Please stand by. Your program is about to begin. Good day, everyone, and welcome to the Assure Holdings third quarter 2022 earnings call. At this time, all participants are in a listen-only mode. Later, you will have an opportunity to ask questions during the question-and-answer session. You may register to ask a question by pressing star and one on your touch tone phone. Please note this call may be recorded. It is now my pleasure to turn today's program over to Scott Kozak, Director of Investor Relations. Please go ahead. Hello, everyone. Thank you for participating in today's conference call to discuss Assure Holdings financial results for the third quarter 2022. On the call today are Executive Chairman and CEO, John Farlinger, and CFO, John Price. After market close this afternoon, the company issued a press release announcing its results for the third quarter 2022. The release and investor presentation are available on the investor section of our website. Before we begin the prepared remarks, I would like to remind you that some of the statements made will be forward-looking and are made under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected or implied due to a variety of factors. We refer you to Assure's recent filings with the SEC, including our quarterly report on Form 10-K for the fourth quarter and full year for a more detailed discussion of the risks that could impact the company's future operating results and financial condition. Also on today's call, management will reference certain non-GAAP financial measures, which we believe provide useful information for investors. For a reconciliation of these non-GAAP measures, please consult the most recently filed Form 8-K associated with the filing of the earnings release for the three months ended September 30, 2022, which is available on the SEC website. Finally, I would like to remind everyone who dialed into the call by telephone, you may want to join our webcast or download our third quarter 2022 earnings presentation on Assure's investor relations site found at ir.assureneuromonitoring.com in order to see the slides referenced today. This call will be recorded and made available for replay via link and on the company's website. Now, I would like to turn the call over to the Executive Chairman and CEO of Assure Holdings, John Farlinger. John? Thank you, Scott. Hello, everyone, and thanks for joining us today. On Slide 3 in front of you'll see the agenda of key topics we'll cover on today's earnings call. I will begin with a review of recent corporate developments and then talk about the intraoperative neuromonitoring industry environment before transitioning to a discussion on cash receipts. Then our CFO, John Price, will go through financial results and discuss accounts receivable trends. I will wrap up with a discussion around fourth quarter 2022 expectations. Assure's third quarter results improved operationally. However, these results were masked by the diminishing effect of accounting basis-related challenges and charges. Overall, Assure is laying the foundation for what we believe will be further improvement in the fourth quarter of 2022. Assure has continued growing our managed case volume and maintained accelerated cash collections during the quarter, underscoring the underlying strength of the business. To support these results, the company utilized market intelligence and data warehousing analytics we did not previously possess to inform our decision to exit slower-performing markets that were dragging down our average revenue and margin per case. Our go-forward strategy is anchored on achieving the benefit of scale in geographies underpinned by the above average commercial health insurance reimbursement obtained. These combined actions are expected to lower our 2022 managed cases from 25,000 to a range of 21,000-22,000, while at the same time improving the company's utilization, margin, and profitability. To be clear, Assure was on track to perform 25,000 cases in 2022, but management chose to forego a segment of volume in order to focus on profitable growth and improving margins. Even with the reduced forecast, our managed case volume in full year 2022 is expected to increase between 21% and 26% compared to 2021. In addition, a key focus for Assure in the fourth quarter of 2022 will be on reducing the company's average cost of delivery for providing our services both on the technologist and the remote neurology portions of our business. We've also taken steps to become leaner and more profitable, continuing a strategic cost reduction effort that will yield more than $5 million of annualized savings compared to the first quarter of this year. Assure expects to further reduce cash burn in the fourth quarter of 2022. This reflects our focus on becoming self-sustaining from a cash flow perspective in the near term. Assure reported substantial progress on its accounts receivable reserve, reporting $2.1 million in the third quarter after reporting a combined $14.1 million in the first half of this year. In addition, Assure strengthened its financial position and created runway to capitalize on our most promising growth opportunities by closing an underwritten public offering with net proceeds to the company of approximately $5.8 million. Despite macroeconomic headwinds and a challenging environment for microcap stocks. I'm pleased to report that this financing was completed as a straight-up sale of equity without warrants. Finally, we're also pleased to extend our footprint in the state of New Jersey, which also demonstrates a very strong reimbursement profile. Our ability to secure new business with a surgeon of the stature of Dr. Marc Levine reflects the strong reputation that we have built in the IOM industry, which is really focused on providing outstanding clinical care. On Slide 5, I will relay an update on the intraoperative neuromonitoring industry. The reimbursement environment in the intraoperative neuromonitoring industry has shifted significantly. We've begun to see contraction in the technical bill even before the COVID pandemic began. Over the past 12 months, as commercial insurance payers sought to leverage their position ahead of the implementation of the No Surprises Act and the ramping up of federal arbitrations, including the dispute resolution processes intended to help level the playing field between payer and provider, we have seen payers play hardball to try to force the intraoperative neuromonitoring providers to take unfavorable in-network agreements or accept delayed payment or even non-payment for services. This was particularly felt on the technical bills and the technical portion of our business, which, as a reminder, is compensation for technologists providing intraoperative neuromonitoring services in the operating room. From Assure's perspective, the amount of AR relating to the technical claims dropped from $18.9 million at December 31, 2021 to $9.5 million at September 30, 2022. The value of the AR has dropped because payors have pushed down the associated levels of reimbursement for technical claims. As a result, Assure's moved aggressively to maximize collections on the professional bill or more specifically, compensation for remote neurology services provided by Assure. We're also moving away from the master services agreement or MSA model so that we can keep all collections from the professional bill. We are accelerating this initiative during the fourth quarter. Anticipating this trend, Assure had already been moving in the direction with the launch of our remote neurology business services in the second quarter of 2021. Our focus is leveraging a dedicated platform to provide neurology services to make sure we are able to fix costs and ensure margin. Where this is heading from industry perspective is that intraoperative neuromonitoring providers with sophisticated revenue cycle management will know with a high degree of certainty what they are going to receive for services provided. The next steps for Assure are clear. We are aligning our costs with updated managed case revenue expectations. We're adding scale in favorable markets. We are leveraging state and federal arbitration programs and augmenting and supporting those with data-driven revenue cycle management functions that will lead to ultimately signing in-network agreements to speed up cash flow and improve participation rates. Lastly, we want to leverage and take advantage of an opportunistic M&A environment in an industry that appears likely to see substantial near-term consolidation. On Slide 6, you will see Assure's substantial increase in total cash collections over a trailing six, 12, and 24-month period. For 100% on net Assure entities, the company is collecting approximately 65% of its cash in the first 6 months and 85% in the first 12 months. Both of these figures maintain the record rates the company has generated in recent quarters. Importantly, we are collecting what we are accruing on the front end. Assure is driving higher participation rates, shortened cash cycles, and better collections. Accelerating our cash flow reduces our need for working capital and also serves to minimize reserves in the future. Cash collected also supports our accrual rates and supports earnings. The company has built a sophisticated data-driven revenue cycle management function in-house, and we are collecting rapidly. In contrast, most of our competitors in the neuromonitoring space still depend on third-party billing providers. The last point I will add on cash receipts is that Assure has far better data and visibility on reimbursement than we had previously. We are leveraging that information to inform and educate ourselves on what markets we should be scaling. States like New Jersey, which we are now entering, and we're also identifying new states and ranking and prioritizing them as we expand in the future. Assure is focused on identifying and adding scale where we can achieve the best margin, work with the best payers, and collect reimbursement with the least friction. Further, we expect to see improvement in their intraoperative neuromonitoring reimbursement rates as the dispute resolution process associated with the No Surprises Act, federal legislation that went into effect earlier this year, begins to have an impact during the fourth quarter of this year and into 2023. Next, John Price will walk us through the quarterly financials. John? Thanks, John, and thank you everyone for joining us today. On S lide 7, I will provide color on financial results from our third quarter 2022. Assure continued to generate procedure growth, performing 5,300 managed cases during the period, an increase over prior year Q3, despite Assure exiting certain low performing markets during the period. Assure reported gross revenue of $8.3 million and net revenue of $6.2 million. Adjusted EBITDA loss of $1.2 million and net loss of $1.4 million. The reserve of aged receivables netted against current quarter revenue negatively impacted our financial results in the third quarter, although by a much lesser degree than it did in the first half of this year. The company's operating expenses was $3.8 million, and we expect costs to be reduced further in the fourth quarter. In addition, Assure collected approximately 64% more cash in Q3 2022 compared to Q3 2021 at $7.2 million versus $4.4 million. Another item I'd like to mention is that Assure's understanding of the value of a managed case has improved considerably, driven by an increasingly sophisticated revenue cycle management function and data analytics. Next, on Slide 8, we will look at Days Sales Outstanding. In this table, we see that Assure's DSOs have decreased dramatically from nearly 600 days during a COVID-impacted 2020 to 343 days in the third quarter of 2022. We are simply collecting cash faster. As a result, there is significantly reduced exposure to future accounts receivable reserves. While we are pleased with this reduction in DSOs, there is still room for improvement. We are focused on driving this significantly lower from current levels. Next on Slide 9, we will look at trends in accounts receivable aging by quarter. Comparing the time periods, you can see that in the third quarter, Assure has 76% of its outstanding accounts receivable in the 12 months or less bucket. In comparison, during the first quarter of 2022, just 68% of AR was categorized as 12 months or less. What this shows was by the end of Q3, a much larger proportion of our accounts receivable are in what we consider a current bucket of 12 months or less compared with earlier this year. The shift of the accounts receivable towards the current bucket reduces Assure's exposure and susceptibility to future reserves. As John mentioned earlier, we are collecting what we are accruing for on the front end. We are turning the corner here and have better visibility into the risk of this type of reserve occurring again. With that said, I'd like to remind investors that in the fourth quarter of 2021. Assure formalized a new holistic accounts receivable accrual and reserve strategy based on our historical collection experience. The new process provides a clearer picture of our estimated collectible AR by taking a conservative approach and reserving claims earlier in the process rather than waiting for the legacy 24-month threshold. The benefit of taking these reserves earlier is, one, it provides clear visibility into future accounts receivable write-down expense. Two, our anticipated go-forward exposure in 2023 is substantially reduced because there is less residual accounts receivable. As we continue to accelerate our cash receipts and DSOs to under 300 days, there is less AR at risk. The downside of this new process is that it has led to higher than anticipated reserves in fiscal 2022. Now I'll pass the call back over to John Farlinger for expectations fourth quarter in 2022. John? Thanks, John. On Slide 10, we provide a guidance forecast for the fourth quarter of 2022. With the third quarter, we expect the fourth quarter to be much cleaner, certainly with respect to reserves compared with the first half of 2022. Starting at the top, we see managed case volume of approximately 4,800-5,800 procedures. This total reflects continued growth in key geographies, as well as the impact of exiting less profitable markets to support our profitability and cash flow goals. Q4 results will benefit from the seasonality of our business, including a ramp up of case volume and a more beneficial revenue mix with a higher proportion of patients utilizing more profitable commercial insurance programs. Relative to the proportion of government insurance patients. Our accounts receivable reserve is $2 million in the third quarter and was in line with expectations. We are hoping for a reserve of less than $3 million in the fourth quarter. Overall, in the fourth quarter of 2022, we anticipate a far narrower gap between gross revenue and net revenue compared to what we've experienced in the first half of 2022. On the cost side, Assure will continue to see a reduction in operating costs in the fourth quarter as we benefit from the administrative and other operational cuts we have made. We are going to continue to cut costs and run leaner in the fourth quarter. Further, we will no longer be burdened by severance expense associated with actions taken earlier this year to make our business leaner. Finally, we see continued strength in collections as we further accelerate collections on new claims and improve collections on aged accounts receivable. Taken together, Assure is focused on significantly reducing its AR reserve, substantially lowering its cost structure, and generating higher quality managed case volume centered on going deeper in our more profitable markets. We've also worked to fix the cost of our cases going forward with an impetus on driving those costs lower. We expect that these factors will continue our progress on running leaner and reducing cash burn in the fourth quarter of 2022. In October, we experienced a meaningful decrease in the Texas reimbursement benchmark, which has been utilized in state arbitration claims to great success through September of this year. At this point, Texas state arbitration reimbursement has been realigned to a level much closer to the state average across our operational footprint. As a reminder, Texas is Assure's largest market and represents approximately 60% of our patient volume. The company's focused on improving margin and increasing participation rates for state arbitrations in Texas. This change does not affect the larger pool of federal arbitrations associated with Texas still to come. This pool is anticipated to be much larger than the pool of state arbitration claims. One final comment I want to make relates to the M&A environment. It is ripe with opportunity and highly favorable for buyers. Assure seeks targets with operations in states where we have existing profitable presence, as this helps us leverage our existing employee footprint, utilization, and revenue cycle management competencies. I expect Assure will be active in the M&A marketplace. With that, I'll turn the call back over to our operator for Q&A. Thank you. At this time, if you'd like to ask a question, please press star and one on your touch tone phone. You may remove yourself from the queue at any time by pressing star two. Once again, that is star and one. We'll take our first question from Jim Sidoti from Sidoti & Company. Jim, your line is open. Sorry about that. Hi, John. Thanks for taking the questions. You've done a lot to adapt to the changes in the industry. You've improved revenue cycle management. You've implemented data analytics. You know, how is the rest of the industry adapting at this point? That's a good question. Jim, I think, you know, what we've been experiencing is what the rest of the industry is experiencing as well. You know, we saw a shift in reimbursement probably going back to last year, really hitting home this year, really the focus there being on technical claims, lower propensity to pay out on technical and the need to really be all in on the professional side and the remote neurology side of the business. Where this is going is really a model which is going toward really forced settlements through arbitrations at a state level, at a federal level. If you don't have data, if you don't have analytics, you're gonna be at a significant disadvantage going into next year. A lot of our success this year has been predicated at least from improving cash flow and stabilizing earnings from the data analytics portion, where it's allowed us to arbitrate hundreds of cases. We haven't lost one yet, and we're just getting into the federal claims now because there's been such a backlog of claims. For the most part, that's been really done at the state level. What we're seeing is really most of the market, at least the smaller competitors, are still using them. You know, I keep going back to the third-party billing companies. They're still using them. We probably looked at six targets where they're still using third-party billing companies. They don't have data. They don't have analytics. These companies don't even have the ability to arbitrate. Without that, they're gonna be at a significant disadvantage going into next year. We think it's gonna be a very tough winter for a lot of companies in the space. I think the other thing that the payers have done in advance of the No Surprises Act and really the full scale of arbitrations hitting, they've attempted to push reimbursement down and slow payments down in an attempt to try to control the reimbursement environment. If you don't have data, if you don't have analytics, if you can't automate and drive more revenue through arbitrations and settlements, it's gonna be very difficult to survive. I think that's why we're feeling pretty good. As we look at competitors, we look at acquisitions and M&A, we feel that for the most part, we can snap these potential opportunities onto our platform and get a higher yield than the existing companies are. That's why we're optimistic about M&A. We think that'll be a key part of what our business plan and model looks like in early 2023. As you scale up and as the revenue shifts from the technical side to the professional side of the business, you know, where do you think margins start to go in 2023 and 2024? Yeah. You probably haven't. I know there were some delays in getting the Q out. As you look at the Q, you will see a significant shift in the amount of technical revenue that we generated from last year to this year. You will see significant growth on the professional side. Really where we're going is really inverting the model that we had here, that the business was set up around, which was really around monetizing the technical claims and really sharing the revenue on the professional side with surgeons. That's a model that we wanna get away from. We wanna control the professional side, and really, we're in the middle of migrating completely away from that rev share. If you look at the queue, you look at where we were a year ago, now almost 70% of our revenue is in non-rev share models and partnerships. We wanna by Q1, we wanna have really all of that revenue off of those partnerships. Ultimately, as you shift toward the remote neurology piece, as you get away from a rev share, we think there's meaningful upside in margins going forward. You know, the business started off by giving away 70, 80, 90% of that professional revenue. We've attempted to shift that model and drive it to a model where we're actually keeping all that remote neurology revenue going forward. That's the other thing I will say. Most of the competitors we're looking at that are potentially for sale are still tied to that old model of keeping the tech revenue, giving away the professional revenue, and facing lower and lower yields. It's pretty clear to us now that we were right last fall in that the model will shift to a global bill, and you've got to keep as much of that professional revenue as possible. Hence, that'll be a key part of what we do. Obviously, as you do more and more scale on the remote neurology piece, you potentially are facing higher margins, at least on the pro side. I think we're at a point in time now on the tech side, we're just trying to make that part of our business profitable and to cover costs. On the pro side, there is significant upside still to get higher margins. Okay. During the quarter, you expanded into New Jersey. Are there any other regions you think you'll be expanding into in the fourth quarter in 2023? No. I think in Q4, we're focused on a couple things. Reducing costs. We're in the middle of continuing to reduce costs, improving utilization of our techs. We wanna get a higher yield on the technical side because it is a business that's under the most duress. Expanding, really expanding in the existing markets we're in Texas, Colorado. We want to add business in New Jersey, which is one of the highest reimbursement states in the United States. It's top five. Okay. I mean, with regard to costs, you're already down, you know, more than 20% from the first quarter, at least in G&A. I mean, does that number continue to trend down, in the fourth quarter? I think there'll be a reallocation of costs. Yes, it'll continue to trend down in the fourth quarter in Q1. There's gonna be a shift in where we spend money in Q1 and Q2 going forward. I think we can still run leaner, and we will run leaner going into Q1. All right. Thank you. Our next question comes from Bill Sutherland from The Benchmark Company. Thank you. Hey, John and John. I was wondering on the DSO trend, it seems like it's moved up from the first half of the year. Is there just a timing issue here? Do you wanna speak to that, John? Yeah, Bill, it just, it's a reflection of the mix. You get a betterment in the mix in the back half of the year. You know, as you roll into Q1 and Q2, as well as acceleration of our cash receipts, that's where you really start to get to see the benefit in the AR aging. Q3, that's where we really expect it to be. As we continue to, you know, push on cash collections, you'll continue to see more of the percentage of accounts receivable in that first through 12-month buckets than in the second half. Okay. On AR reserves, should we think of that as we even go into next year as just an ongoing kind of part of the model? Yeah. As we adopted this new estimation process, really what we're doing is starting to take a portion of the receivable, the bad debt, in the fifth quarter, you know, through the eighth quarter. Whereas previously, we would wait for the accounts receivable to age out past 24 months. I think it's a better reflection to build the reserve relative to, you know, the overall accounts receivable that we'll end up collecting over that period of time. This is the year that we're adopted that change in estimation, and that's why you see a bit more of the bad debt expense coming through this year. Yeah. Bill, what we found in our analysis is that as you collect the money faster, there's less of a tail to collect later. It's obvious. Yeah. What it forced us to do was to accelerate. We didn't wanna have a large tail at the end, 24 months out. We started to take the writing down and the reserving of that AR much earlier. As you look at this year versus, say, last Q3 or last Q4, the shift Q3, Q4, Q1 was an acceleration of cash flow, and really a speeding up of payments. With the result being that there was less collected in quarters 6, 7, and 8. That led us to the conclusion that we should be accelerating it faster rather than letting it age out after 24 months. It's a more conservative model. We may collect some of that cash later, but it led to a faster reserving of the accounts, an accelerated reserving of the accounts receivable. Yeah. I understand what you're doing this year. Now that you've kind of got things, I guess, I don't know what the right word is, you know, right-sized- Normalized. Yeah. 12-24 month window. What is this still gonna be a gross and net revenue kind of, you know, combination that we have in the model going forward? Excuse me. I think so. For a while, we're trying to narrow that gross and net spread. Frankly, where we see the market going is as these arbitrations become expected and normalized, there's really not gonna be a lot of negotiation. You're gonna get what the arbitration metrics dictate you get. Ultimately, I think it's gonna lead to an accelerated discussion around going in-network. Because, you know, we, you know, I think I highlighted, we haven't lost a state arbitration case yet. We know what we're gonna get. Across the table, the insurance companies know what they're gonna pass. I think, you know, we're starting to escalate discussions now where we were offered low amounts of money to go in-network, at least numbers that didn't work for us earlier this year. Conversations are changing now because they know we're gonna get paid, and we know we're gonna get paid. Is it simpler just to simply agree to a number and then reduce the amount of work we've gotta do to collect that money? I think that's part of what we wanna focus on in Q4 of this year and Q1 of next year, and getting a couple of those large payors in Texas to go in-network with us. Well, that would be great. Yeah, I wish you luck with that. Okay. That's all I got, John. Thank you. It appears we have no further questions at this time. I will now turn the call back to John Farlinger for any additional or closing remarks. Thank you. On behalf of the Assure team, we'd like to thank everyone for listening to today's call. Before concluding, I'd like to add a few final comments. The actions Assure has taken are designed to expand the company's profitable growth, reduce costs, and accelerate cash collections. The company is focused on improving margin, profitability, and net cash flow. With that, I'm gonna conclude. We thank all of you for your participation today and look forward to seeing you again during our fourth quarter call. Thank you very much. Thank you, ladies and gentlemen. This concludes today's conference. You may now disconnect.